Trial Profile
Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cook Medical
- 26 Jul 2018 Status changed from active, no longer recruiting to completed.
- 09 Nov 2017 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
- 09 Nov 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.